HilleVax (NASDAQ:HLVX) Stock Price Down 5.3%

HilleVax, Inc. (NASDAQ:HLVX)’s stock price was down 5.3% on Tuesday . The stock traded as low as $13.09 and last traded at $13.17. Approximately 23,761 shares changed hands during trading, a decline of 81% from the average daily volume of 122,535 shares. The stock had previously closed at $13.91.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and set a $28.00 price target on shares of HilleVax in a research note on Thursday, March 21st.

HilleVax Stock Performance

The stock has a market cap of $589.68 million, a PE ratio of -4.12 and a beta of 0.65. The company has a quick ratio of 10.62, a current ratio of 10.62 and a debt-to-equity ratio of 0.10. The firm has a 50 day moving average price of $16.15 and a 200 day moving average price of $14.63.

HilleVax (NASDAQ:HLVX) last posted its earnings results on Wednesday, March 20th. The company reported ($0.78) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.80) by $0.02. As a group, research analysts forecast that HilleVax, Inc. will post -3.22 earnings per share for the current year.

Insider Buying and Selling at HilleVax

In other HilleVax news, Director Aditya Kohli sold 6,000 shares of HilleVax stock in a transaction dated Wednesday, March 20th. The stock was sold at an average price of $164,221.00, for a total value of $985,326,000.00. Following the transaction, the director now owns 807,776 shares in the company, valued at $132,653,782,496. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, insider Robert Hershberg sold 11,597 shares of the business’s stock in a transaction dated Thursday, February 8th. The stock was sold at an average price of $14.93, for a total transaction of $173,143.21. Following the sale, the insider now owns 953,831 shares in the company, valued at $14,240,696.83. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Aditya Kohli sold 6,000 shares of the business’s stock in a transaction dated Wednesday, March 20th. The stock was sold at an average price of $164,221.00, for a total value of $985,326,000.00. Following the sale, the director now owns 807,776 shares in the company, valued at approximately $132,653,782,496. The disclosure for this sale can be found here. Insiders have sold 78,039 shares of company stock worth $986,464,242 over the last quarter. Insiders own 29.30% of the company’s stock.

Institutional Investors Weigh In On HilleVax

A number of large investors have recently modified their holdings of the business. Vanguard Group Inc. grew its stake in shares of HilleVax by 27.0% during the fourth quarter. Vanguard Group Inc. now owns 1,464,840 shares of the company’s stock worth $23,511,000 after acquiring an additional 310,973 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in shares of HilleVax by 17.0% during the fourth quarter. Goldman Sachs Group Inc. now owns 20,314 shares of the company’s stock worth $326,000 after purchasing an additional 2,952 shares during the period. American International Group Inc. lifted its holdings in shares of HilleVax by 23.0% during the fourth quarter. American International Group Inc. now owns 13,031 shares of the company’s stock worth $209,000 after purchasing an additional 2,437 shares during the period. Barclays PLC lifted its holdings in shares of HilleVax by 526.1% during the fourth quarter. Barclays PLC now owns 39,908 shares of the company’s stock worth $640,000 after purchasing an additional 33,534 shares during the period. Finally, Voya Investment Management LLC acquired a new stake in shares of HilleVax during the fourth quarter worth about $166,000. Hedge funds and other institutional investors own 86.42% of the company’s stock.

HilleVax Company Profile

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. The company develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus and related illness. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.